What is FLNA's Value Score?

Filana Therapeutics, Inc. - Common Stock (FLNA) has a StockPik Value Score of 45 out of 100 — a mid-range score, indicating moderate value characteristics. The Value Score is a composite ranking built from P/E ratio, P/B ratio, Graham Number, ROE, gross margin, debt-to-equity, current ratio, and Piotroski F-Score, calculated from SEC EDGAR annual filing data.

What is FLNA's Piotroski F-Score?

Filana Therapeutics, Inc. - Common Stock (FLNA) has a Piotroski F-Score of 1 out of 9 — a weak score indicating financial deterioration across multiple criteria. The F-Score assesses nine binary financial criteria across profitability, leverage, and operating efficiency. A score of 7–9 indicates a financially improving company; a score of 0–3 is a warning sign.

What is FLNA's Piotroski F-Score?

FLNA's Piotroski F-Score is 1 out of 9, indicating weak financial health and possible deterioration. The Piotroski F-Score evaluates nine criteria across profitability, leverage, and operating efficiency. Scores of 7 or above are considered strong; 3 or below indicate financial weakness.

Is FLNA (Filana Therapeutics, Inc. - Common Stock) undervalued?

FLNA scores 45/100 on StockPik's Value Score.

Back to Screener

Filana Therapeutics, Inc. - Common Stock (FLNA)

NASDAQ Micro Cap

$1.73

Market Cap: $84M

Data as of Sep 30, 2025 (TTM)

Investment Snapshot

P/B of 1.12 — trading near book value
Piotroski F-Score 1/9 — signs of financial weakness
Loss-making — negative ROE of -143.0%

Filana Therapeutics, Inc. - Common Stock (FLNA) is a publicly traded company, listed on the NASDAQ , with a market capitalisation of $84 million . Key value metrics: P/B ratio 1.12, Piotroski F-Score 1 out of 9 .

Value Score

out of 100

Try PRO Free — See Full Breakdown

Key Metrics

P/E Ratio

—

P/B Ratio

1.12

EPS

$-2.20

Div. Yield

—

PEG Ratio

—

P/S Ratio

—

EV/EBITDA

—

ROE

—

ROA

—

Gross Margin

—

Op. Margin

—

Net Margin

—

Debt/Equity

—

Current Ratio

—

Unlock 19 More Metrics — 7 Days Free

Data sourced from SEC EDGAR and Polygon.io. Methodology.

Filana Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary

On financial health, FLNA shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and negative return on equity of -143.0%.

StockPik's composite Value Score for FLNA is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.

FLNA shows earnings declining at 274%.

How is the Value Score calculated?

Read our full methodology →

What is the Piotroski F-Score?

The 9-point financial health score explained, with worked examples →

FLL — Full House Resorts, Inc. - Common Stock

Fluence Energy, Inc. - Class A Common Stock — FLNC